Go Pro
→ Wall Street is staring at the wrong AI trade (From The Oxford Club) (Ad)tc pixel Free DERM Stock Alerts

Journey Medical (DERM) Competitors

Journey Medical logo
$6.72 +0.07 (+1.05%)
Closing price 04:00 PM Eastern
Extended Trading
$6.72 0.00 (0.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

DERM vs. FBIO, HELP, PHAT, ACHV, and ZVRA

Should you buy Journey Medical stock or one of its competitors? Journey Medical's main competitors and comparable companies include Fortress Biotech (FBIO), Cybin (HELP), Phathom Pharmaceuticals (PHAT), Achieve Life Sciences (ACHV), and Zevra Therapeutics (ZVRA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Journey Medical compare to Fortress Biotech?

Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Journey Medical had 15 more articles in the media than Fortress Biotech. MarketBeat recorded 22 mentions for Journey Medical and 7 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.86 beat Journey Medical's score of 0.54 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Fortress Biotech
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Journey Medical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

Fortress Biotech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$61.86M2.99-$11.43M-$0.37N/A
Fortress Biotech$63.26M1.54$6.82M$3.170.92

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 28.5% of Fortress Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Journey Medical currently has a consensus target price of $14.00, indicating a potential upside of 108.33%. Fortress Biotech has a consensus target price of $17.00, indicating a potential upside of 480.20%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Fortress Biotech
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Fortress Biotech has a net margin of 163.32% compared to Journey Medical's net margin of -8.95%. Fortress Biotech's return on equity of 101.74% beat Journey Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-8.95% -20.23% -6.60%
Fortress Biotech 163.32%101.74%46.34%

Summary

Fortress Biotech beats Journey Medical on 12 of the 14 factors compared between the two stocks.

How does Journey Medical compare to Cybin?

Journey Medical (NASDAQ:DERM) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Journey Medical has higher revenue and earnings than Cybin. Journey Medical is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$61.86M2.99-$11.43M-$0.37N/A
CybinN/AN/A-$148M-$4.23N/A

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cybin has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Cybin's return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-8.95% -20.23% -6.60%
Cybin N/A -68.27%-58.26%

In the previous week, Journey Medical had 16 more articles in the media than Cybin. MarketBeat recorded 22 mentions for Journey Medical and 6 mentions for Cybin. Cybin's average media sentiment score of 0.93 beat Journey Medical's score of 0.54 indicating that Cybin is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Cybin
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Journey Medical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Journey Medical currently has a consensus price target of $14.00, suggesting a potential upside of 108.33%. Cybin has a consensus price target of $45.25, suggesting a potential upside of 277.40%. Given Cybin's stronger consensus rating and higher probable upside, analysts clearly believe Cybin is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Cybin
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cybin beats Journey Medical on 8 of the 15 factors compared between the two stocks.

How does Journey Medical compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Journey Medical has a net margin of -8.95% compared to Phathom Pharmaceuticals' net margin of -41.34%. Phathom Pharmaceuticals' return on equity of 0.00% beat Journey Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Phathom Pharmaceuticals-41.34% N/A -20.81%
Journey Medical -8.95%-20.23%-6.60%

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phathom Pharmaceuticals has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

In the previous week, Journey Medical had 19 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 22 mentions for Journey Medical and 3 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.73 beat Journey Medical's score of 0.54 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Phathom Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Journey Medical has lower revenue, but higher earnings than Phathom Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phathom Pharmaceuticals$175.11M4.43-$221.25M-$1.28N/A
Journey Medical$61.86M2.99-$11.43M-$0.37N/A

Phathom Pharmaceuticals presently has a consensus price target of $22.86, indicating a potential upside of 138.59%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 108.33%. Given Phathom Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Phathom Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Summary

Phathom Pharmaceuticals beats Journey Medical on 10 of the 17 factors compared between the two stocks.

How does Journey Medical compare to Achieve Life Sciences?

Journey Medical (NASDAQ:DERM) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

In the previous week, Journey Medical had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 22 mentions for Journey Medical and 20 mentions for Achieve Life Sciences. Journey Medical's average media sentiment score of 0.54 beat Achieve Life Sciences' score of 0.16 indicating that Journey Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Achieve Life Sciences
2 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Journey Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market.

Journey Medical presently has a consensus price target of $14.00, indicating a potential upside of 108.33%. Achieve Life Sciences has a consensus price target of $15.00, indicating a potential upside of 97.63%. Given Journey Medical's higher probable upside, equities research analysts clearly believe Journey Medical is more favorable than Achieve Life Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Achieve Life Sciences
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Journey Medical has higher revenue and earnings than Achieve Life Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$61.86M2.99-$11.43M-$0.37N/A
Achieve Life SciencesN/AN/A-$54.65M-$1.55N/A

Achieve Life Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Achieve Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-8.95% -20.23% -6.60%
Achieve Life Sciences N/A -511.12%-82.35%

Summary

Journey Medical beats Achieve Life Sciences on 9 of the 16 factors compared between the two stocks.

How does Journey Medical compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Zevra Therapeutics presently has a consensus price target of $27.14, indicating a potential upside of 139.78%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 108.33%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Zevra Therapeutics is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.82
Journey Medical
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

Zevra Therapeutics has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$106.47M6.31$83.23M$0.9212.30
Journey Medical$61.86M2.99-$11.43M-$0.37N/A

Zevra Therapeutics has a net margin of 42.82% compared to Journey Medical's net margin of -8.95%. Zevra Therapeutics' return on equity of 54.54% beat Journey Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics42.82% 54.54% 34.15%
Journey Medical -8.95%-20.23%-6.60%

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Journey Medical had 5 more articles in the media than Zevra Therapeutics. MarketBeat recorded 22 mentions for Journey Medical and 17 mentions for Zevra Therapeutics. Journey Medical's average media sentiment score of 0.54 beat Zevra Therapeutics' score of 0.26 indicating that Journey Medical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zevra Therapeutics
5 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Journey Medical
2 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Summary

Zevra Therapeutics beats Journey Medical on 12 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DERM vs. The Competition

Export
MetricJourney MedicalPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$183.10M$11.89B$7.06B$13.10B
Dividend YieldN/A2.70%2.57%10.45%
P/E Ratio-30.55640.15211.0921.74
Price / Sales2.99743.87602.9892.99
Price / CashN/A66.4570.4850.90
Price / Book5.7411.6012.916.24
Net Income-$11.43M$2.77B$3.45B$347.60M
7 Day Performance4.51%0.17%1.12%1.07%
1 Month Performance-5.62%0.35%1.79%1.03%
1 Year Performance-7.44%161.52%67.69%20.77%

Journey Medical Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DERM
Journey Medical
2.9277 of 5 stars		$6.72
+1.1%		$14.00
+108.3%		-8.3%$183.10M$61.86MN/A90
FBIO
Fortress Biotech
2.6092 of 5 stars		$2.61
-5.1%		$17.00
+551.3%		+54.4%$91.35M$63.26M0.82170
HELP
Cybin
3.1156 of 5 stars		$10.09
+0.8%		$45.25
+348.5%		N/A$699.44MN/AN/A50
PHAT
Phathom Pharmaceuticals
3.2577 of 5 stars		$8.51
-0.7%		$23.43
+175.3%		-12.3%$693.32M$239.66MN/A110
ACHV
Achieve Life Sciences
2.4948 of 5 stars		$6.77
+1.5%		$16.00
+136.3%		+185.4%$684.74MN/AN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Who Really Gets Rich from IPOs?
Peter Thiel turned a $500,000 stake in Meta into nearly $1 billion by investing eight years before its IPO. Tr...
Weiss Ratings | Sponsoredtc pixel
$100 for this… $500 for that. Here’s how to stop the bleeding today
Rising costs are squeezing households nationwide. USA Today reports more families are moving in together, whil...
Brownstone Research | Sponsoredtc pixel